Jundong Li

State Key Laboratory Of Oncology In South China
Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR-T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy.

PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR-T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: March 25, 2026

Sentinel-Lymph-Node Biopsy Alone or with Lymphadenectomy in Cervical Cancer.

Sentinel-Lymph-Node Biopsy Alone or with Lymphadenectomy in Cervical Cancer.

Journal: The New England journal of medicine

Published: October 15, 2025

Tisotumab vedotin versus chemotherapy in Chinese patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy.

Tisotumab vedotin versus chemotherapy in Chinese patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy.

Journal: Chinese medical journal

Published: September 22, 2025

Patient-reported outcomes after long-term period of niraparib maintenance in platinum-sensitive recurrent ovarian cancer: a prospective, multicenter cohort study.

Patient-reported outcomes after long-term period of niraparib maintenance in platinum-sensitive recurrent ovarian cancer: a prospective, multicenter cohort study.

Journal: Journal of ovarian research

Published: May 21, 2025

Safety, pharmacokinetic, pharmacodynamic, and efficacy properties of orally administered APG-2449 in patients with advanced ALK + and ROS1 + non-small-cell lung cancer: a multicentre, open-label, single-arm phase 1 trial.

Safety, pharmacokinetic, pharmacodynamic, and efficacy properties of orally administered APG-2449 in patients with advanced ALK + and ROS1 + non-small-cell lung cancer: a multicentre, open-label, single-arm phase 1 trial.

Journal: EClinicalMedicine

Published: May 08, 2025

Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial.

Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial.

Journal: Nature cancer

Published: April 09, 2025

Development of a prognosis model for PARP inhibitor therapies based on multiple genomic alterations associated with homologous recombination deficiency in ovarian cancer.

Development of a prognosis model for PARP inhibitor therapies based on multiple genomic alterations associated with homologous recombination deficiency in ovarian cancer.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: April 08, 2025

Spatiotemporal Immune Determinants of Response to Immune Rechallenge in Advanced Cervical Cancer.

Spatiotemporal Immune Determinants of Response to Immune Rechallenge in Advanced Cervical Cancer.

Journal: Cancer discovery

Published: March 18, 2025

Simplifying surgical criteria for early-stage cervical cancer: prognostic equivalence of total vs. radical hysterectomy in a retrospective SEER cohort analysis.

Simplifying surgical criteria for early-stage cervical cancer: prognostic equivalence of total vs. radical hysterectomy in a retrospective SEER cohort analysis.

Journal: International journal of surgery (London, England)

Published: February 24, 2025

The comparison of efficacy and safety between cadonilimab (PD-1/CTLA-4) and anti-PD-1 inhibitors in patients with recurrent or metastatic cervical cancer: a retrospective real-world study.

The comparison of efficacy and safety between cadonilimab (PD-1/CTLA-4) and anti-PD-1 inhibitors in patients with recurrent or metastatic cervical cancer: a retrospective real-world study.

Journal: Frontiers in immunology

Published: February 24, 2025

Secondary Cytoreductive Surgery for Ovarian Cancer With Second Platinum-Sensitive Recurrence: A Multicentre Retrospective Cohort Study.

Secondary Cytoreductive Surgery for Ovarian Cancer With Second Platinum-Sensitive Recurrence: A Multicentre Retrospective Cohort Study.

Journal: BJOG : an international journal of obstetrics and gynaecology

Published: November 28, 2024

Follow-up of hereditary endometrial carcinoma caused by MLH3 gene mutation: a case report.

Follow-up of hereditary endometrial carcinoma caused by MLH3 gene mutation: a case report.

Journal: Frontiers in oncology

Published: November 22, 2024

Showing 1-12 of 33

Last Updated: 09/26/2026